Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 study of AG-013736 (axitinib) in Japanese patients with advanced solid tumors.

Next Previous
X
Search
Trial Profile

A phase 1 study of AG-013736 (axitinib) in Japanese patients with advanced solid tumors.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 11 Jan 2019 Results characterizing the physiological and molecular characteristics driving variability in axitinib AUCSS using physiologically based pharmacokinetic modeling using data from Pfizer trials (A4061019, A406010, A4061022, A4061036, A4061044, A4061055, A406105) published in the Journal of Clinical Pharmacology
    • 22 Sep 2009 Actual end date (August 2009) added as reported by ClinicalTrials.gov.
    • 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top